Brief: Molecular Templates Announces IND Acceptance By FDA For MT-8421 ETB Program
09/03/2023 21:29
March 9 (Reuters) - Molecular Templates Inc MTEM.O :
* MOLECULAR TEMPLATES ANNOUNCES IND ACCEPTANCE BY FDA FOR
MT-8421
ETB PROGRAM TARGETING CTLA-4
* MOLECULAR TEMPLATES INC - MTEM EXPECTS TO INITIATE A
FIRST-IN-HUMAN PHASE I STUDY WITH MT-8421 BY MID-YEAR 2023 AT A
STARTING DOSE OF 32 MCG/KG
Source text for Eikon: ID:nGNX6xsj3m
Further company coverage: MTEM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Molecular Templates
See all newsBrief: Molecular Templates Co & Affiliate Commenced Chapter 11 Cases As DIP
Brief: Molecular Templates's Eric E. Poma Resigns As CEO, CSO, Treasurer, And Interim CFO
Brief: Molecular Templates Announces Notice Of Delisting And Failure To Satisfy Continued Listing Rules
Brief: Molecular Templates Announces Receipt Of Expected Notification Of Deficiency From Nasdaq
Brief: Molecular Templates Approved Liquidation & Wind Up Through A Dissolution